CDC Guidelines for the Prevention and Treatment of Anthrax, 2023

William A. Bower, MD 1 ; Yon Yu, PharmD 2 ; Marissa K. Person, MSPH 1 ; Corinne M. Parker, PharmD 2 ; Jordan L. Kennedy, MSPH 1 ; David Sue, PhD 2 ; Elisabeth M. Hesse, MD 2 ; Rachel Cook, MS 1 ; John Bradley, MD 3 ; Jürgen B. Bulitta, PhD 4 ; Adolf W. Karchmer, MD 5 ; Robert M. Ward, MD 6 ; Shana Godfred Cato, DO 7 ; Kevin Chatham Stephens, MD 8 ; Katherine A. Hendricks, MD 1 (View author affiliations)

Article Metrics
Altmetric:
Citations:
Views:

Views equals page views plus PDF downloads

On This Page Tables Related Materials

Summary

This report updates previous CDC guidelines and recommendations on preferred prevention and treatment regimens regarding naturally occurring anthrax. Also provided are a wide range of alternative regimens to first-line antimicrobial drugs for use if patients have contraindications or intolerances or after a wide-area aerosol release of: Bacillus anthracis spores if resources become limited or a multidrug-resistant B. anthracis strain is used (Hendricks KA, Wright ME, Shadomy SV, et al.; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis 2014;20:e130687; Meaney-Delman D, Rasmussen SA, Beigi RH, et al. Prophylaxis and treatment of anthrax in pregnant women. Obstet Gynecol 2013;122:885−900; Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. Pediatrics 2014;133:e1411-36). Specifically, this report updates antimicrobial drug and antitoxin use for both postexposure prophylaxis (PEP) and treatment from these previous guidelines best practices and is based on systematic reviews of the literature regarding 1) in vitro antimicrobial drug activity against B. anthracis; 2) in vivo antimicrobial drug efficacy for PEP and treatment; 3) in vivo and human antitoxin efficacy for PEP, treatment, or both; and 4) human survival after antimicrobial drug PEP and treatment of localized anthrax, systemic anthrax, and anthrax meningitis.

Changes from previous CDC guidelines and recommendations include an expanded list of alternative antimicrobial drugs to use when first-line antimicrobial drugs are contraindicated or not tolerated or after a bioterrorism event when first-line antimicrobial drugs are depleted or ineffective against a genetically engineered resistant: B. anthracis strain. In addition, these updated guidelines include new recommendations regarding special considerations for the diagnosis and treatment of anthrax meningitis, including comorbid, social, and clinical predictors of anthrax meningitis.

The previously published CDC guidelines and recommendations described potentially beneficial critical care measures and clinical assessment tools and procedures for persons with anthrax, which have not changed and are not addressed in this update. In addition, no changes were made to the Advisory Committee on Immunization Practices recommendations for use of anthrax vaccine (Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep 2019;68[No. RR-4]:1–14). The updated guidelines in this report can be used by health care providers to prevent and treat anthrax and guide emergency preparedness officials and planners as they develop and update plans for a wide-area aerosol release of B. anthracis.

Introduction

Anthrax is a zoonotic disease caused by infection with Bacillus anthracis and still occurs in agricultural regions of the Americas, sub-Saharan Africa, central and southwestern Asia, and southern and eastern Europe (1). Sheep, goats, cattle, and other herbivores are primarily affected. Humans are secondarily infected through contact with infected animals, contaminated animal products (e.g., meat or hides), or, rarely, from injection drug use (2). Anthrax in humans usually is characterized by the route of B. anthracis inoculation (3). Cutaneous anthrax, which results from direct inoculation of spores through the skin, is the most common form and accounts for >95% of human cases. Ingestion anthrax usually results from consumption of infected meat. Inhalation anthrax results from the inhalation of aerosolized spores. Injection anthrax, which is a relatively new form, results from injection of heroin contaminated with B. anthracis spores. Anthrax meningitis can complicate any form of anthrax or occur alone.

In the United States, anthrax has almost been eliminated through livestock vaccination. Wildlife and livestock anthrax still occurs sporadically in an area from southwest Texas through Colorado, North and South Dakota, and Montana (4,5). Since 2006, nine confirmed or probable U.S. cases of anthrax have been reported to CDC: two inhalation (6,7), one ingestion (8), four cutaneous (9,10), and two with no documented route of infection. In addition, since 1997, seven cases of severe pneumonia have been identified that were caused by Bacillus cereus group species that harbor a plasmid that encodes anthrax toxins similar to those found in B. anthracis (11).

B. anthracis is a Tier 1 select agent and considered one of the most likely bioterrorism agents to be used because it is relatively easy to acquire from the natural environment, mass produce, and disseminate as spores via aerosolization (12). Although approximately 180 countries have signed on to the 1975 Biological Weapons Convention prohibiting the development, production, acquisition, transfer, stockpiling, and use of bioweapons, a wide-area aerosol release of B. anthracis spores remains a concern. In 2001, B. anthracis spores were sent in letters through the U.S. Postal Service. Exposure to aerosolized spores in these letters resulted in 11 inhalation and 11 cutaneous cases; five inhalation cases were fatal (13,14). A wide-area aerosol release of B. anthracis spores would likely result in a mass-casualty incident (15,16) that could possibly be complicated by use of genetically engineered B. anthracis strains resistant to first-line antimicrobial drugs for postexposure prophylaxis (PEP) and treatment. In 2015, CDC published recommendations for hospital-based acute care that addressed antitoxin and intravenous (IV) antimicrobial drug use and the diagnosis and management of common anthrax-specific complications during a mass-casualty incident that would require a shift from conventional to contingency or crisis standards of care (17).

B. anthracis possesses three primary virulence factors: an extracellular capsule and two bipartite exotoxins (lethal toxin [composed of lethal factor and protective antigen] and edema toxin [composed of edema factor and protective antigen]) (18–20). The capsule prevents phagocytosis of the vegetative form of B. anthracis by macrophages, allowing it to evade the immune system. The two toxins also facilitate immune system evasion by disrupting various immune cell functions (e.g., cellular signaling and cell migration) (21,22). In addition, they impair macrophages, neutrophils, and dendritic cell functions (23,24) and inhibit host B- and T-cell immune responses (25). Lethal toxin causes apoptosis of endothelial cells within the vascular system and is thought to contribute to hemorrhage (26). These combined effects allow bacterial proliferation and lead to the high morbidity and mortality associated with anthrax. Historically, antiserum appeared to be an effective treatment. In aggregate data from the preantibiotic era, patients with cutaneous anthrax who were treated with antiserum had a substantially lower mortality rate than those who remained untreated (7.6% for patients who received antiserum during 1903−1941 compared with 23.7% for patients who did not receive antiserum during 1888−1920) (27).

Before the bioterrorism-related inhalation anthrax cases in 2001 (13), the anthrax mortality rate for the cases before the 1960s approached 90% for inhalation anthrax (28) and neared 100% for anthrax meningitis (29). Mortality rates have improved with advancements in critical care; however, even with treatment, mortality ranges from 30), to 45% for inhalation anthrax (28), and to 92% for anthrax meningitis (30). In a mass-casualty event after a wide-area aerosol release of B. anthracis spores, mortality rates potentially could resemble those observed before the advent of modern critical care.

In 2013 and 2014, CDC published guidelines and recommendations for PEP and treatment of anthrax in pregnant and lactating persons (31), nonpregnant adults (27), and children (32). Those guidelines incorporated published and unpublished data from in vitro studies and U.S. inhalation anthrax cases since 2001 and also relied on expert opinion. In addition to addressing PEP and treatment of anthrax across all populations, those previously published guidelines described potentially beneficial critical care measures and clinical procedures for persons with anthrax, which are not addressed in this report. The ACIP recommendations for the use of anthrax vaccine remain unchanged (33). Vaccination of persons at risk for anthrax infection (e.g., travelers and laboratorians) can prevent disease. For unvaccinated or incompletely vaccinated persons exposed to B. anthracis, PEP includes both antimicrobial drugs with activity against B. anthracis (PEPAbx) and anthrax vaccine (PEPVx). This report updates best practices from previous guidelines for antimicrobial drug and antitoxin use for both PEP and treatment. The updated guidelines in this report are based on systematic reviews of the literature and associated data analyses regarding in vitro antimicrobial drug activity against B. anthracis; in vivo antimicrobial drug efficacy for PEPAbx and treatment; in vivo and human antitoxin efficacy for PEP, treatment, or both; and human survival after PEPAbx and treatment of localized anthrax, systemic anthrax, and anthrax meningitis. A review of safety information for the Food and Drug Administration (FDA)-approved antimicrobial drugs under consideration also served as a basis for the updated guidelines. Furthermore, these updated guidelines include new recommendations regarding special considerations for the diagnosis and treatment of anthrax meningitis, including comorbid, social, and clinical predictors of meningitis. This report recommends use of the following antimicrobial drugs that are not approved by FDA for anthrax PEPAbx or treatment: amoxicillin, amoxicillin/clavulanate, ampicillin/sulbactam, chloramphenicol, clarithromycin, clindamycin, dalbavancin, eravacycline, imipenem/cilastatin, linezolid, meropenem, moxifloxacin, ofloxacin, omadacycline, penicillin VK, piperacillin/tazobactam, rifampin, and vancomycin. Ciprofloxacin, doxycycline, levofloxacin, minocycline, penicillin G, and tetracycline are approved by FDA for anthrax PEPAbx, treatment, or both, but the specific uses (e.g., doses and dosing schedules) recommended in this report might differ from the FDA-approved labeling.

The intended audiences for the guidelines in this report are primary care providers and public health professionals. The antimicrobial drug, antitoxin, and other recommendations for PEP and treatment are best practices for the clinical management of single patient cases or limited outbreaks of naturally acquired anthrax. In addition, these guidelines address the issue of B. anthracis strains resistant to previously recommended antimicrobial drugs. Extensive antimicrobial drug options are provided for situations when first-line antimicrobial drugs are not tolerated or are contraindicated or after a bioterrorism event involving a wide-area aerosol release of B. anthracis spores over a heavily populated area. The latter might require a shift to crisis standards of care when supplies of first-line antimicrobial drugs have been depleted.

Methods

To update the guidelines in this report, CDC established a CDC team to conduct systematic reviews and convened multiple work groups with external experts to review the data. CDC held meetings with the work groups to solicit information from individual members rather than obtain consensus from the whole group. After the review of the evidence and consideration of suggestions from members of the work group, CDC finalized the guidance and recommendations in this report. The composition and charge for each work group are described as follows:

Systematic Reviews

The data used to update the CDC anthrax clinical guidelines were based mainly on four systematic reviews of the literature performed by the Anthrax Clinical Guidelines Team. For each systematic review, database searches were supplemented with studies identified through hand searching of references and communication with additional subject matter experts. The data from all systematic and other reviews were abstracted and summarized for outcomes of interest.

The first systematic review was an all-language review of B. anthracis in vitro antimicrobial drug susceptibility studies published during 1947–2019 (34). For this systematic review, studies were considered for further assessment only if they reported B. anthracis minimum inhibitory concentration (MIC) values that were measured by using standard laboratory conventional broth microdilution, broth macrodilution, or agar dilution methods as described by the Clinical and Laboratory Standards Institute (CLSI) or European Committee on Antimicrobial Susceptibility Testing guidelines. Any study that reported MIC values for B. anthracis strains and cited agar-based gradient strip MIC testing (e.g., Etest and Lilofilchem) following the manufacturer’s instructions also was considered for further assessment. This review included antimicrobial drugs with IV, intramuscular (IM), or oral formulations that were both commercially available in the United States and approved by FDA (although not necessarily for anthrax PEPAbx or treatment). The second all-language systematic review summarized antimicrobial drugs used in animal studies for PEPAbx or treatment of experimental infections with virulent B. anthracis published during 1947–2019 (35). The third systematic review updated a previous in vivo and clinical systematic review of anthrax antitoxin for treatment of inhalation anthrax (36) and was restricted to English-language articles published during 2015–2019 (37). In contrast to the original systematic review (36) that focused on antitoxin use for inhalation anthrax, this systematic review also included database searches from date of inception through 2014 for articles on PEP for animals and treatment of humans with systemic noninhalation anthrax.

The fourth systematic review was restricted to articles describing patients hospitalized for anthrax published in English during 1880–2018 (38). All human data were observational in nature. Cases were categorized into localized versus systemic disease. “Systemic illness” included evidence of organ damage or any of the following signs: hyperthermia or hypothermia, tachycardia, tachypnea, hypotension, or leukocytosis or leukopenia (30). Sensitivity analyses were performed when necessary to assess whether heterogeneity of case report quality affected results. Subsets of the data from this systematic review were analyzed for clinical (38), treatment (39), and cutaneous anthrax outcomes (40) and for the development of an anthrax meningitis screening tool (41).

A full systematic review of safety information was not conducted for two reasons. First, the antimicrobial drugs being considered were FDA approved, commercially available, and had safety profiles that were based on clinical usage data. Second, safety reviews of certain antimicrobial drugs had been conducted for the 2014 anthrax and 2021 plague guidelines. Instead, existing drug safety data sources were reviewed for 24 selected antimicrobial drugs under consideration for PEPAbx or treatment of anthrax, or both (42). Data from these tertiary sources were supplemented through focused PubMed searches. For antimicrobial drugs FDA approved before 2010, literature published in English during January 2018–April 2021 was identified via PubMed and reviewed for randomized controlled trials (RCTs) describing serious or severe adverse events (AEs) in adults, pregnant and lactating persons, and children. The criteria used to identify the severe or serious AEs for inclusion in the safety review of selected antimicrobials are defined in a previous publication (i.e., severe or serious AEs reported in the literature as possibly related, probably related, related, or definitely related to the study treatment, or if causality was not reported and causality could not be obtained from the authors) (42). For antimicrobial drugs that were FDA approved in 2010 or later, English-language literature identified in PubMed from inception through April 2021 was reviewed for all study types (i.e., RCTs, observational studies, and case series or case reports) describing serious or severe AEs in adults, pregnant and lactating persons, and children. Because of the limited data available in tertiary data sources for antimicrobial drugs FDA approved in 2010 or later, no date restrictions were applied to these literature searches. In addition, PubMed search terms captured all literature related to antimicrobial drug use in pregnant and lactating persons and children and were not specifically limited to serious or severe AEs.

Univariate and multivariable logistic regression was used to calculate odds ratios (ORs) with 95% CIs comparing the odds of survival between different treatments. For the in vivo systematic review (35), data were extracted from independent studies and combined into meta-analyses when multiple studies evaluated the same antimicrobial drugs. These data were used to estimate an overall OR and 95% CI for successful therapy. Data analyses were performed in SAS (version 9.4; SAS Institute), and p43,44) were performed for in vivo animal efficacy studies of antimicrobial drugs when sufficient data were available.

Review of the Evidence

The Anthrax Clinical Guidelines Team summarized systematic review data for review by the Anthrax Work Group during twice-monthly meetings held during December 2019–June 2021. In June 2021, CDC held 3 days of virtual meetings that included members of the Anthrax Work Group plus additional experts in anthrax, infectious diseases, pediatrics, obstetrics, pharmacology, and emergency response to review available scientific information and provide individual-level input on proposed CDC updates to previously published guidelines for prevention and treatment of anthrax. Additional specialties represented included biostatistics, critical care, emergency medicine, geriatrics, neurocritical care, neurosurgery, and preventive medicine. All internal CDC staff members involved in developing the guidelines and external consultants providing individual input submitted a written financial disclosure statement reporting any potential conflicts of interest related to questions discussed during the consultations or concerns involved in developing the updated CDC anthrax guidelines. The Anthrax Work Group co-chairs reviewed each reported association for potential competing interests and determined the appropriate action, as follows: disqualification from the panel, disqualification/recusal from topic review and discussion, or no disqualification needed. A competing interest was defined as any direct financial interest related to a product addressed in the section of the guidelines to which a panel member contributed content. Financial interests included direct receipt by the panel member of payments, gratuities, consultancies, honoraria, employment, grants, support for travel or accommodation, or gifts from an entity having a commercial interest in that product. Financial interest also included direct compensation for membership on an advisory board, data safety monitoring board, or speaker bureau. Compensation and support filtered through a panel member’s university or institution (e.g., grants or research funding) was not considered a competing interest. All federal employees, including CDC staff members, are subject to the Standards of Ethical Conduct for Employees of the Executive Branch (45).

The meeting attendees listened to presentations on anthrax clinical features (38), optimal antimicrobial drug treatment and PEP from both an efficacy (in vitro, in vivo, and observational clinical data) and safety standpoint (34,35,39,42,46,47), the value and use of antitoxins (37,39,48–50), and methods to rapidly identify and optimally treat anthrax meningitis (39–41,51,52). The attendees then provided individual expert opinions on proposed edits to previous antimicrobial drug and antitoxin PEP and treatment guidelines.

When evaluating the benefit versus harm of antimicrobial drugs for anthrax (PEP, treatment, or both), risks common to all antimicrobial drugs (e.g., hypersensitivity, Clostridioides difficile infection and associated diarrhea, and selective pressure for colonization and subsequent infection by resistant organisms) were considered in the risk-benefit evaluation. Additional considerations included specific AEs for each antimicrobial drug and antimicrobial drug class and patient- and population-specific characteristics that influence antimicrobial drug selection (e.g., renal function, drug allergies, and interacting concomitant medications).

Individual expert opinions on prophylaxis and treatment options were collated for later internal CDC discussions. After the meeting, the Anthrax Clinical Guidelines Team drafted narrative summaries, recommendations, and tables. The guideline authors shared the draft guidelines with the anthrax work groups and refined the proposed changes to the guidelines based, in part, on their feedback. This report summarizes the presentations and discussions from the meeting and updates previous CDC guidelines for prevention and treatment of anthrax.

Summary of Key Findings

In Vitro B. anthracis Antimicrobial Drug Susceptibility Testing

A systematic review identified 105 sources describing in vitro B. anthracis antimicrobial drug susceptibility testing representing results for 169 different compounds (34). After articles were excluded for incomplete MIC data or nonstandard methodology, 39 remained that contained data on 43 antimicrobial drugs of interest. Except for aztreonam, ceftriaxone, and trimethoprim/sulfamethoxazole, most antimicrobial drugs appeared useful per the CLSI guidelines (i.e., had low MICs for B. anthracis in comparison with clinically relevant unbound drug concentrations) ( Table 1). Omadacycline was identified as a potentially effective option for certain tetracycline-resistance mechanisms (e.g., efflux pumps) because unpublished in vitro data have indicated it might evade these mechanisms. Naturally occurring high-level resistance was observed in multiple studies of penicillin-class antimicrobial drugs, eight of eight studies of a representative cephalosporin (i.e., ceftriaxone), and five of five studies of trimethoprim/sulfamethoxazole.

In Vivo PEPAbx and Treatment of Anthrax

A systematic review identified 62 sources on in vivo PEPAbx and treatment of anthrax that described approximately 800 study arms with approximately 12,000 animals (35). After exclusions, data were analyzed from 37 sources that described 33 antimicrobial drugs and 309 study arms with 3,450 animals, including 1,423 mice, 807 rabbits, 660 hamsters, 329 nonhuman primates, and 231 guinea pigs. Antimicrobial drugs expected to be effective for PEPAbx or treatment of anthrax were identified by examining the odds of survival for selected antimicrobial drugs compared with untreated or ciprofloxacin- or doxycycline-treated controls (35) ( Table 2). Efficacy of clinically relevant dosage regimens was predicted for antibiotics with sufficient PK and anthrax PEPAbx or treatment efficacy data.

PEP

Meta-analyses and most individual animal studies that could not be combined into any of the meta-analyses found a survival benefit for PEPAbx compared with no PEPAbx for amoxicillin, amoxicillin/clavulanate (two of three studies), ciprofloxacin, dalbavancin, daptomycin, doxycycline, imipenem, minocycline, ofloxacin, omadacycline, oritavancin, and tetracycline. Of four studies on macrolide-class antimicrobial drugs, only one study that evaluated azithromycin demonstrated a benefit. No statistically significant benefit was identified for cefazolin, chloramphenicol, gentamicin, levofloxacin, penicillin, and trimethoprim/sulfamethoxazole when used in a PEPAbx model. When compared with positive controls, minocycline performed better than doxycycline, and oritavancin performed less well than ciprofloxacin. Included PEPAbx studies used aerosol exposures, except for those using cefazolin, gentamicin, imipenem, ofloxacin, and trimethoprim/sulfamethoxazole (which used intranasal challenges) and those that included chloramphenicol and erythromycin ethylsuccinate (which used intraperitoneal challenges). For PEPAbx against naturally occurring B. anthracis infection in humans, Monte Carlo simulations predicted that unbound drug exposures adequately covered the MICs required to inhibit the growth of 90% of organisms (MIC90) for ciprofloxacin, doxycycline, and levofloxacin; dalbavancin only covered the MICs required to inhibit the growth of 50% of organisms (MIC50).

Treatment

The in vivo meta-analyses and studies that could not be combined into any of the meta-analyses demonstrated a survival benefit for monotherapy compared with no treatment for amoxicillin/clavulanate, ciprofloxacin, clindamycin, dalbavancin, doxycycline, eravacycline, imipenem, omadacycline, oritavancin, penicillin, and vancomycin. Clarithromycin, levofloxacin, linezolid, and rifampin did not demonstrate a statistically significant survival benefit when compared with no treatment. One rabbit model for anthrax meningitis indicated a survival benefit for amoxicillin/clavulanate and ampicillin with or without sulbactam. A second rabbit model for anthrax meningitis demonstrated a survival benefit for clindamycin. For treatment of naturally occurring anthrax in humans, Monte Carlo simulations predicted that unbound drug exposures adequately covered the MIC90 for ciprofloxacin, doxycycline, and levofloxacin (JS Bradley, MD, University of California San Diego School of Medicine, JB Bulitta, PhD, University of Florida College of Pharmacy, personal communication, November 2022).

Antitoxins for PEP and Treatment of Anthrax

A systematic review identified 757 sources that reported on use of anthrax antitoxins in prevention or treatment of systemic anthrax disease (37). After screening the titles and abstracts for relevant articles and applying exclusion criteria, data were abstracted from 14 papers.

PEP

Animal data indicated that PEP with any of the anthrax antitoxins (i.e., anthrax immunoglobulin intravenous [AIGIV; polyclonal] and obiltoxaximab and raxibacumab [both monoclonal]) provided a statistically significant survival benefit (p53–56).

Coadministration With Anthrax Vaccine Adsorbed

Although data indicated that the polyclonal antitoxin AIGIV should not be coadministered with anthrax vaccine adsorbed (AVA) (57), noninterference was demonstrated between raxibacumab and AVA, allowing their coadministration (58). No data were available on coadministration of obiltoxaximab and AVA.

Adjunctive Treatment

A head-to-head comparison of the three antitoxins for treatment after aerosol exposure to B. anthracis in an animal model demonstrated a survival benefit compared with placebo. No differences were observed in survival between the monoclonal antitoxins obiltoxaximab and raxibacumab, but both monoclonals were considerably more effective than the polyclonal antitoxin AIGIV (50). However, this animal model did not use the highest FDA-approved AIGIV dose. The higher dose might have lessened the survival difference for the monoclonal antitoxins compared with the polyclonal antitoxin (37).

In animal models, treatment with the polyclonal or either monoclonal antitoxin provided a statistically significant (p≤0.0001for all three antitoxins) survival benefit compared with no treatment. However, adding the polyclonal antitoxin or either monoclonal antitoxin to antimicrobial drugs did not significantly improve survival over antimicrobial drugs alone (59–61).

Human Data for PEPAbx of Anthrax

In an observational study conducted in the former Soviet Union, persons exposed to anthrax-affected animals were administered PEPAbx with a penicillin or tetracycline (62). After noninhalation exposure, 17% of 339 persons who did not receive PEPAbx developed anthrax. In contrast, only 1.7% of 287 persons who received a short course (i.e., 3 days) of PEPAbx developed anthrax (p<0.001). After this finding, when various PEPAbx regimens were used in 407 persons exposed to B. anthracis, none developed anthrax.

Human Clinical and Treatment Data for Anthrax

A systematic review identified 13,082 sources of human clinical and treatment data on patients hospitalized for anthrax (30,38). After removal of duplicates and review of titles and abstracts for relevance, 952 full-text articles were reviewed; 584 were excluded because they lacked data on patients with confirmed anthrax who were hospitalized or died. The remaining 368 articles (composed of case reports, case series, and line lists) yielded 965 adult and pediatric patients with confirmed anthrax who were hospitalized or died. Two separate analyses were performed on this data set of 965 patients, one focused on the clinical aspects of anthrax (38) and the other on treatment (39).

Therapies evaluated in the treatment systematic review (39) included antimicrobial drugs, antiserum/antitoxin, steroids, and mannitol. To analyze antimicrobial drug use during the era of modern clinical care, the database was restricted to adult cases published during 1940–2018 (N = 303). Analyses of adult cases were restricted to 1900–2018 (N = 422) for antiserum/antitoxin use, 1950–2018 (N = 253) for steroid use, and 1960–2018 (N = 232) for mannitol use.

Treatment in Hospitalized Adults

In adult patients hospitalized for anthrax, monotherapy, including penicillin monotherapy, resulted in a high survival rate (98%) for those with localized cutaneous anthrax (39). For adults with systemic cutaneous anthrax without meningitis, survivorship was high if they received any treatment; only one patient in this category died. Survival with penicillin monotherapy was 89% for those with systemic illness from any route if they did not have meningitis. Adults with inhalation anthrax without meningitis fared poorly with monotherapy; only 17% (one of six) survived compared with 70% (seven of 10) with combination therapy. For anthrax meningitis, neither antimicrobial drug monotherapy nor combination therapy was particularly effective; only 21% (three of 14) survived with monotherapy and 17% (three of 18) with combination therapy. However, both monotherapy and combination therapy were more effective than no therapy.

Multivariable analysis of survival for systemically ill patients administered specific therapies suggested effective treatment options (39) ( Table 3). After controlling for shock and altered mental status, odds of survival among systemically ill patients with anthrax were higher for those receiving bactericidal antimicrobial drugs alone compared with protein synthesis inhibitors (PSIs) alone (p = 0.047). In addition, when controlling for hypoxia, shock, and altered mental status (i.e., illness severity), odds of survival were not improved by adding a PSI to a bactericidal antimicrobial drug. Odds of survival also were not improved by adding a second class of antimicrobial drug or an antitoxin to an antimicrobial drug.

Survivorship was compared in steroid recipients and nonrecipients with various complications. For patients with shock, survivors included zero of two (0%) recipients and six of 17 (35%) nonrecipients. For patients with head or neck involvement, survivors included four of seven (57%) recipients and 38 of 45 (84%) nonrecipients. For those with edema involving more than one extremity, survivors included four of eight (50%) recipients and 24 of 29 (83%) nonrecipients. Survivorship generally was higher among nonrecipients, suggesting steroids were not beneficial in these specific risk groups.

Antitoxins with or without antimicrobial drugs at any point throughout hospitalization could not be demonstrated to improve outcomes. After controlling for age and illness severity, the odds of survival were not different for recipients compared with nonrecipients (adjusted OR = 1.49; 95% CI = 0.73–3.05).

Complications

Multiple clinically relevant complications might occur in association with anthrax (38). Sepsis developed in approximately 70% of patients with systemic disease. Approximately one fourth of adults hospitalized with systemic cutaneous or ingestion anthrax and one third with inhalation anthrax developed secondary meningitis. Evidence of coagulopathy was reported in approximately one third of adults with ingestion, inhalation, and injection anthrax and those with primary meningitis. Arrhythmias occasionally were observed, most commonly in adults with inhalation anthrax (7%). Respiratory failure requiring ventilation often occurred in adults with injection anthrax (32%) and inhalation anthrax (23%). Severe disease was associated with diabetes, obesity, hypertension, and chronic obstructive pulmonary disease (p50).

Similar to adults, complications of anthrax in children varied by site of initial infection (38). Sepsis developed in 60%–84% of children with inhalation, ingestion, and systemic cutaneous anthrax. Secondary meningitis was observed in 25% of children with systemic disease associated with cutaneous anthrax, 40% with inhalation anthrax, and 30% with ingestion anthrax. Coagulopathy occurred in approximately 40% of inhalation and ingestion cases.

Many adults developed clinically relevant fluid collections (38). Although pleural effusion was most commonly a complication of inhalation anthrax (76%), it also occurred in 3%–10% of patients with ingestion, systemic cutaneous, and injection anthrax and primary anthrax meningitis. In 2006 and 2011, spectrographic analysis of pleural fluid from patients with inhalation anthrax demonstrated the presence of anthrax lethal factor, one of the three protein components of anthrax toxin. In both patients, lethal factor levels in the pleural fluid exceeded concurrently measured levels in plasma and serum (63,64). Ascites was observed in 52% of adults with ingestion anthrax; in 4% of those with inhalation anthrax; and in one person each with injection anthrax, systemic cutaneous anthrax, and primary anthrax meningitis (38). Ascites also is thought to serve as a reservoir for lethal factor. Pericardial effusions were noted in 21% of patients with inhalation anthrax.

Survival and Length of Stay

During 1940–2018, the mortality rates in adults were 92% (22 of 24) for primary anthrax meningitis, 75% (36 of 48) for inhalation anthrax, 72% (23 of 32) for ingestion anthrax, 33% (19 of 58) for injection anthrax, and 22% (45 of 206) for cutaneous anthrax. In children, the mortality rates were 100% (two of two) for primary anthrax meningitis, 100% (two of two) for inhalation anthrax, 48% (11 of 23) for ingestion anthrax, and 8% (nine of 110) for cutaneous anthrax.

During 1940–2018, adults who died tended to do so quickly, with a median hospital stay of only 1 day (IQR = 1–3 days), whereas those who survived had a median stay of 14 days (IQR = 9–22 days). Among adults who survived, median stays for those with localized cutaneous anthrax were 11 days (IQR = 8–16 days); systemic anthrax without meningitis, 16 days (IQR = 10–29 days); and with meningitis, 19 days (IQR = 12–32 days) (39).

Studies of Hospitalized Patients with Cutaneous Anthrax

Antimicrobial Drug Selection

In a case series from the Kyrgyz Republic, 230 patients were hospitalized for cutaneous anthrax during 2005–2012; all 167 with mild illness and 43 of 44 with moderate illness received monotherapy and survived (52). The remaining patient with moderate illness and all 19 patients with severe illness received dual therapy and survived. No patient received triple therapy.

Signs and Symptoms Predictive of Fatal Outcome

A systematic review of reported cases among adults hospitalized for cutaneous anthrax during 1950–2018 found that presenting clinical features significantly associated with overall mortality on univariate analysis included constitutional symptoms (e.g., fever, chills, and anxiety), specific dermatologic issues (e.g., skin trauma, thoracic edema, and malignant pustule edema), diastolic hypotension, nausea and vomiting, headache and other neurologic signs (e.g., cranial nerve and other focal signs and seizures), and evidence of a coagulopathy (p<0.05) (40). Lymphadenopathy was associated with fatal outcomes within the first 3 days of hospitalization, and abdominal pain was associated with later fatal outcomes. Bacteremia noted at any point throughout hospitalization was associated with overall mortality.

Special Considerations for the Diagnosis and Treatment of Anthrax Meningitis

Comorbidities and Social History Predictive of Meningitis

In the Kyrgyz Republic case series, 126 of the 230 patients with cutaneous anthrax could be categorized by a clinical (i.e., signs and symptoms) algorithm into likely or not likely meningitis (52). Obesity, diabetes, hypertension, and chronic obstructive pulmonary disease were associated with likely meningitis. In addition, former and current smoking and former alcohol use were associated with likely meningitis.

Signs and Symptoms Predictive of Meningitis

Three recent studies (two of which shared overlapping data sets) have examined presenting signs, symptoms, and laboratory results associated with anthrax meningitis (40,41,52) ( Table 4). One study evaluated systemic anthrax in adults (41) and two evaluated cutaneous anthrax in adults (40,52). All three studies found that fever and chills, nausea and vomiting, and headache were associated with meningitis. Two studies also found nonheadache, nonmeningeal neurologic signs (e.g., seizures and cranial nerve signs) to be associated with meningitis. Predictors found in one study included altered mental status and meningeal signs, fever (>38.0°C or >100.4°F), tachypnea (>20 breaths per minutes), tachycardia (≥100 beats per minute), systolic and diastolic hypertension (≥130 and ≥90 mm Hg, respectively), and evidence of coagulopathy. Presenting bacteremia was predictive of meningitis in one of the studies and bacteremia at any point throughout hospitalization was predictive in another.

Triage Tool for Predicting Meningitis in a Mass Casualty Event

In 2016, a study described a 4-item anthrax meningitis assessment (i.e., screening) tool that included severe headache, altered mental status, meningeal signs, and other neurologic signs (30). Using this tool, patients were deemed likely to have meningitis if two or more of the items were present and unlikely to have meningitis if no items were present. Patients with only one of the items were in a middle group that would need diagnostic testing (e.g., imaging and lumbar puncture) to determine their meningitis status.

A study (41) validated the meningitis screening tool (30) and another evaluated newly identified risk factors (40). On re-evaluation, the 2016 screening tool had a sensitivity of 86% (95% CI = 71%–100%) and a specificity of 99% (95% CI = 97%–100%). However, >17% of adults still needed further diagnostic workup to determine presence or absence of meningitis. A new, more complex screening tool was developed to minimize the number of patients who would require further testing ( Figure). This screening tool had a sensitivity of 86% (95% CI = 71%–100%) and a specificity of 92% (95% CI = 85%–99%) but left only 2.5% of adults in need of further testing (41).

Antimicrobial Drug Selection

In the Kyrgyz Republic case series, 37 patients were categorized by an algorithm as likely having meningitis and 89 were considered unlikely to have meningitis (52). Twenty-three (62%) of the 37 received monotherapy, and all 23 survived. The remainder (38%) received 2-drug combination therapy and survived. Only five of 14 survivors who received combination therapy received a bactericidal and a PSI antimicrobial drug, and none received three concurrent antimicrobial drugs.

In the systematic review of human treatment data, survival was not improved by adding a PSI to a bactericidal antimicrobial drug in adults with anthrax meningitis (39). However, median length of stay for the three patients who received both a PSI and a bactericidal antimicrobial drug was 10 days (IQR = 8–21 days) compared with 30 days (IQR = 15–50 days) for the four who received bactericidal antimicrobial drugs alone, although this difference was not statistically significant (p = 0.26) (39).

Population PK Modeling to Predict Drug Exposures in Cerebrospinal Fluid for Naturally Occurring B. anthracis Strains

Antimicrobial drugs with published human cerebrospinal fluid (CSF) penetration data were categorized according to their ability to achieve robust drug exposures in both plasma and CSF based on population PK modeling followed by Monte Carlo simulations. Because PK/PD target values for B. anthracis are scarce, established targets from other pathogens were used to evaluate drug exposures. One study suggested the PK/PD targets for the carbapenem class of antibiotics (e.g., faropenem) were comparable between B. anthracis and gram-negative pathogens. The blood-brain barrier can be impaired considerably during anthrax meningitis; therefore, both the plasma and the CSF exposures were considered. Because of the need for between-pathogen extrapolations of PK/PD targets, absence of CSF-specific targets, and relative sparsity of the data, these Monte Carlo simulation results should be interpreted conservatively.

The Monte Carlo simulations indicated the probability that patients with suspected or documented anthrax meningitis would achieve microbiologic cure of CSF when treated with the recommended dosage was high (≥95%) for ampicillin, ampicillin/sulbactam, ciprofloxacin, doxycycline, imipenem/cilastatin, levofloxacin 500 mg every 12 hours, meropenem, minocycline, and penicillin G; acceptable (≥90% to <95%) for levofloxacin 750 mg every 24 hours and piperacillin/tazobactam; and low (˂90%) for clindamycin, linezolid, and vancomycin ( Table 5). Despite poor coverage for bacterial killing, the reduced toxin production provided by PSIs (e.g., clindamycin and linezolid) might still be of benefit and should be part of combination therapy.

Intracerebral Hemorrhage With Anthrax Meningitis

Anthrax meningitis is often accompanied by destruction of the blood-brain barrier and intracranial bleeding and swelling (51). Subarachnoid hemorrhage is a common complication (51). Meningeal seeding and a metalloprotease of B. anthracis that targets the tight junctions of the blood-brain barrier contribute to destruction of the barrier and cerebral hemorrhage. Both animal experimental models and case reports suggest that intracranial hemorrhage is common when B. anthracis infection involves the brain (65,66). The infection combined with neurotoxicity of intracranial blood likely leads to rapid brain swelling and the poor outcomes observed among these patients (67).

Recent progress has been made in the treatment of aneurysmal subarachnoid and spontaneous intracerebral hemorrhage. Nimodipine is the only drug approved by FDA for aneurysmal subarachnoid hemorrhage and reduces the incidence of poor neurologic outcome by 40% (68). In vivo studies also have suggested nimodipine might be beneficial in treating pneumococcal meningitis (69,70). Although these principles of neurointensive care and treatment regimens are used routinely in patients with bleeds, they appear to have seldom been applied in patients with anthrax meningitis. Patients with anthrax meningitis might benefit from standard treatment for intracerebral hemorrhage.

Certain antimicrobial drugs demonstrated to have neuroprotective effects in other diseases or models might be useful for anthrax meningitis. For example, minocycline is a highly lipophilic second-generation tetracycline that readily crosses the blood-brain barrier and has been observed in vivo to have neuroprotective effects against subarachnoid hemorrhage (71–75), intracerebral bleeding (76–81), and blood-brain barrier disruption (71,74–76,81–89). Theoretically, minocycline might be beneficial for the treatment of anthrax meningitis because of its anti-inflammatory, antiapoptotic, and antioxidant effects (90–92). Other antimicrobial drugs with in vivo neuroprotective effects for certain meningitides include ß-lactams (93), clindamycin (94), and daptomycin (95,96).

Cerebral Edema in Anthrax Meningitis

In adult patients with systemic anthrax, the odds of survival for the steroid and no steroid groups did not statistically differ after adjusting for age and severity (39). For adults with meningitis, survival was not different in those who received steroids (two of six) compared with those who did not (three of 39; OR = 6.00; 95% CI = 0.76–47.36). However, patients who received mannitol had higher odds of survival than those who did not (OR = 24.00; 95% CI = 1.66–347.85). For example, two of the rare survivors of anthrax meningitis received mannitol or mannitol with hyperosmolar therapy (49,97). In addition, bacterial meningitis studies in animal models found that 3% hypertonic saline reduces intracranial pressure, improves cerebral perfusion pressure, inhibits aquaporin-4 expression, reduces cerebral edema, and attenuates neuronal injury. This suggests hypertonic saline might be beneficial for the treatment of symptomatic cerebral edema (98).

Review of Safety Data for Antimicrobial Drugs and Antitoxins Proposed for PEPAbx and Treatment of Anthrax

When evaluating the benefit of antimicrobial drugs for PEPAbx or treatment of anthrax, or both, risks common to antimicrobial drugs (e.g., hypersensitivity, C. difficile infection and associated diarrhea, and selective pressure for colonization and subsequent infection by resistant organisms) should be considered in the risk-benefit evaluation. Additional considerations should include specific adverse events for each antimicrobial drug and antimicrobial drug class and patient- and population-specific characteristics that influence antimicrobial drug selection (e.g., renal function, drug allergies, and interacting concomitant medications). The recommended antimicrobial drugs have known or potential serious or severe risks that might influence their selection and prioritization for PEPAbx or treatment of anthrax across different patient populations. The safety review that evaluated 24 selected antimicrobials under consideration for PEPAbx or treatment of anthrax, or both, concluded that, for the reviewed antimicrobial drugs, because of the considerable morbidity and mortality associated with anthrax, the risk-benefit evaluation favors their consideration for anthrax, provided risk-mitigation measures are implemented as warranted (40).

Fluoroquinolones

Warnings for all fluoroquinolones include risk for central nervous system effects (e.g., serious psychotic reactions), tendon rupture and tendonitis, peripheral neuropathy, aortic aneurysm and dissection, hepatotoxicity, and altered cardiac conduction. Older persons might be at increased risk for these AEs. Although fluoroquinolones generally are not recommended for routine first-line use in pregnant persons and children, multiple studies found that the fluoroquinolones were well tolerated in the pediatric population (99–102). In addition, an American Academy of Pediatrics report supports use of fluoroquinolones in children when clinically necessary (103).

Tetracyclines

Penicillins

The penicillin class is generally well tolerated in all populations. A previous FDA review supported the safety of long-term penicillin and penicillin-derivative use (106).

Carbapenems

Serious AEs associated with the carbapenem class (especially imipenem/cilastatin) include seizure. For this reason, imipenem/cilastatin is not advised for treatment of infections involving the central nervous system (107,108). If treatment with imipenem/cilastatin is needed for anthrax meningitis, antiepileptic agents can be added to reduce seizure risk, including in the pediatric population (109).

Other Antimicrobial Drugs

The prolonged use of clindamycin for PEP might increase the risk for C. difficile infection and associated diarrhea (110–112). The prolonged use of linezolid for PEP might increase the risk for myelosuppression, lactic acidosis, and potentially irreversible optic neuritis and peripheral neuropathy (113,114).

Anthrax Antitoxins

AIGIV can cause thrombosis and false high readings with certain point-of-care blood glucose testing systems (115). Both obiltoxaximab and raxibacumab can cause hypersensitivity reactions and anaphylaxis (116–118). Patients receiving either monoclonal antitoxin should be premedicated with diphenhydramine.

CDC Recommendations for Prevention and Treatment of Anthrax

Anthrax can be a devastating disease. In one Russian series, one in six patients with cutaneous or ingestion exposures to B. anthracis developed anthrax (62). Mortality rates for adequately treated anthrax range from 119) for cutaneous anthrax to 45% for inhalation anthrax (13,120) and >90% for anthrax meningitis (29,52). On the basis of efficacy described from in vivo data and human clinical experience and known potential risks, the benefits of antimicrobial drugs for PEP or treatment of anthrax outweigh the known risks.

These guidelines address anthrax PEP and treatment for both natural and intentional exposures (e.g., a wide-area aerosol release of B. anthracis spores). The evidence base linking recommendations to data is available (Supplementary Material, https://stacks.cdc.gov/view/cdc/132182). Previously, all B. anthracis strains from a naturally occurring source or an intentional release were thought to be susceptible to the recommended first-line antimicrobial drugs (except for penicillins). However, over the past few decades, studies have demonstrated that antimicrobial-resistant B. anthracis strains can be created with relative ease through serial passaging on selective media (121,122). Consequently, bioterrorists could mass produce a multidrug-resistant B. anthracis strain capable of evading previously recommended first-line antimicrobial medical countermeasures. These updated CDC guidelines provide PEP and treatment recommendations that include numerous antimicrobial drugs from multiple classes. The antimicrobial drugs recommended as first-line agents are expected to address most scenarios. The alternative antimicrobial drugs provide contingencies for contraindications, intolerances, unavailability, and natural or genetically engineered resistance.

The recommended medical countermeasures are preferentially ordered based on 1) in vitro effectiveness against B. anthracis (34) (Table 1); 2) in vivo efficacy against B. anthracis exposures as demonstrated by ORs and CIs for survival compared with no therapy or therapy with a positive control (35,37) (Table 2); 3) the animal model used to generate efficacy data (nonhuman primate or rabbit models were preferred over mouse, guinea pig, or hamster models); 4) treatment outcomes for published human cases (39) (Table 3); 5) the percentage of patients expected to achieve microbiologic CSF cure at recommended antimicrobial drug dosing based on Monte Carlo simulations (Table 5); 6) the safety profiles of the antimicrobial drugs (42); 7) logistical considerations (e.g., available formulations [including availability and palatability of liquid formulations], dosing intervals, cost, and supply and availability patterns); and 8) expert opinion. In addition, certain antimicrobial drugs are included for PEPAbx or treatment on the basis of class efficacy (e.g., levofloxacin, moxifloxacin, and ofloxacin) or for treatment on the basis of demonstrated PEPAbx efficacy (e.g., minocycline).

Early diagnosis of anthrax and initiation of appropriate treatment are critical to improving survival. Although empiric treatment of anthrax or prophylaxis after exposure is needed to save lives, antimicrobial drug susceptibility testing is vital; antimicrobial drug choices might need to be modified based on the results. Data indicate penicillin-class antimicrobial drugs are as effective as other bactericidal agents for PEPAbx and treatment and might be preferred in certain populations. However, although B. anthracis isolates are reported to be resistant to penicillin-class antimicrobial drugs (123–126), these drugs should only be used if the strain is known to be penicillin susceptible. In vitro data demonstrate that cephalosporins, trimethoprim/sulfamethoxazole, and aztreonam are ineffective against B. anthracis. If liquid formulations are not available for children or adults who cannot swallow pills, instructions are available for preparing oral suspensions of moxifloxacin (127) and doxycycline (128).

Nonpregnant Adults Aged ≥18 Years

PEP and Treatment Regimens for Cutaneous Anthrax Without Signs and Symptoms of Meningitis

PEP regimens for nonpregnant adults aged ≥18 years exposed to B. anthracis include either a single antimicrobial drug or, if antimicrobial drugs are not available, a single anthrax antitoxin ( Table 6). Both antimicrobial drugs and antitoxins are highly effective at preventing disease in animals. However, because antitoxins are administered intravenously and are somewhat (i.e., the monoclonals) to moderately (i.e., the polyclonal) less efficacious than antimicrobial drugs (35,37), all oral antimicrobial drugs are preferred over antitoxins. In addition, in a wide-area aerosol release of B. anthracis spores, antitoxins should be prioritized for treatment rather than PEP because they likely provide greater benefit as adjunctive treatments. If coadministration of anthrax vaccine and antitoxin is indicated, the only antitoxin that should be used is raxibacumab (37).

Studies in animal models (129,130) and a report after an accidental wide-area aerosol release of B. anthracis spores (15) suggest the incubation period for inhalation anthrax in those administered PEPAbx might be up to 60 days. To prevent anthrax after discontinuation of PEPAbx, ACIP recommends AVA for adults aged 18–65 years in conjunction with a course of PEPAbx (33). AVA is administered subcutaneously at 0, 2, and 4 weeks postexposure; it can be administered intramuscularly if the subcutaneous route poses significant materiel, personnel, or clinical challenges. AVA can be used under an appropriate regulatory mechanism (e.g., investigational new drug or emergency use authorization) in persons aged 65 years exposed to anthrax. In July 2023, a second-generation anthrax vaccine, anthrax vaccine adsorbed, adjuvanted, was FDA approved for PEPVx against inhalation anthrax. Anthrax vaccine adsorbed, adjuvanted is administered by the IM route as a 2-dose series 2 weeks apart, in conjunction with PEPAbx for adults aged 18–65 years. In persons aged >65 years, anthrax vaccine adsorbed, adjuvanted elicited a higher immune response compared with AVA (131). Anthrax vaccine use in older adults (aged >65 years), pregnant or lactating persons, and children (aged

For nonpregnant adults aged ≥18 years, antimicrobial drug monotherapy can be used for treatment of both localized and systemic cutaneous anthrax if the patient does not have signs and symptoms of meningitis (37) ( Table 7). A penicillin-class antimicrobial drug can be used as monotherapy if the organism is known to be penicillin susceptible, which will allow combination regimens to be reserved for patients with high-mortality forms of anthrax (e.g., inhalation anthrax). Anthrax antitoxin can be used to treat cutaneous anthrax without signs and symptoms of meningitis if all recommended antimicrobial drugs are not available or not appropriate.

For nonpregnant adults aged ≥18 years, empiric PEP (Table 6) and empiric cutaneous anthrax treatment (Table 7) regimens include either a single antimicrobial drug or a single antitoxin and are summarized as follows: